CDK4 and breast cancer: In addition, FGFR inhibition may reverse resistance to endocrine therapy and anti-CDK4/6 therapy, and since 26.4% of FGFR1-amplified BC has been found to have PIK3CA alterations [26], it may be combined with inhibitors of the PI3K pathway.